使用贝利尤单抗治疗的系统性红斑狼疮患者的不同妊娠结局。
Different pregnancy outcomes in patients with systemic lupus erythematosus treated with belimumab.
作者信息
Lai Yupeng, Li Bin, Huang Jiaming, Du Jingning, Yue Mengli, Shen Xin, Liu Xingjiao, Huang Lingfeng, Lin Jiehua, Yang Aicheng, Wang Meiying
机构信息
Department of Rheumatology and Immunology, 499778Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China.
Department of Nephrology, The Affiliated Jiangmen TCM Hospital of Jinan University, Jiangmen, China.
出版信息
Lupus. 2023 Jan;32(1):149-154. doi: 10.1177/09612033221141805. Epub 2022 Dec 5.
OBJECTIVES
Systemic lupus erythematosus (SLE) predominantly occurs in women of child-bearing age. Selecting drugs for pregnant SLE patients has always been a difficult choice. Although there have been several reports of safety of belimumab in SLE patients during pregnancy, the data are far from sufficient.
METHODS
We report on 4 cases of belimumab exposure in pregnant SLE patients. We also summarized 6 case reports and case series which were previously published. Further, we compared the different outcomes among SLE patients and their babies who continued with belimumab during pregnancy with those who discontinued belimumab in early pregnancy.
RESULTS
Two cases discontinued belimumab in the early pregnancy, while the other two received belimumab until the late pregnancy. All the four women tolerated belimumab. Newborns have all developed normally and continue without complications during 1 year of follow-up.
CONCLUSION
In this small case series, we found that belimumab was well tolerated in pregnant SLE patients. There were no safety signals for the mothers or their babies.
目的
系统性红斑狼疮（SLE）主要发生在育龄女性中。为妊娠SLE患者选择药物一直是个艰难的抉择。虽然已有几篇关于贝利尤单抗在妊娠SLE患者中安全性的报道，但数据还远远不够。
方法
我们报告了4例妊娠SLE患者暴露于贝利尤单抗的病例。我们还总结了之前发表的6例病例报告和病例系列。此外，我们比较了妊娠期间继续使用贝利尤单抗的SLE患者及其婴儿与早期停用贝利尤单抗的患者之间的不同结局。
结果
2例患者在妊娠早期停用了贝利尤单抗，另外2例患者持续使用贝利尤单抗至妊娠晚期。所有4名女性对贝利尤单抗耐受性良好。新生儿均发育正常，在1年的随访中未出现并发症。
结论
在这个小病例系列中，我们发现妊娠SLE患者对贝利尤单抗耐受性良好。对母亲或其婴儿均无安全信号。
Zotero 插件